Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer

British Journal of Cancer

Volumn 85, Issue 12, 2001, Pages 1878-1882

  Nicoll, G ^a   Crichton, D N ^b   McDowell, H E ^a   Kernohan, N ^a   Hupp, T R ^a   Thompson, A M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Breast cancer; HIC 1; Hypermethylation; p53; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE REPRESSION; HETEROZYGOSITY LOSS; HIC 1 GENE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TELOMERE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BREAST NEOPLASMS; CARCINOMA; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0035555893     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2163     Document Type: Article

References (26)

1. Comparitive allelotype of in situ and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinomas
2. Mice deficient in the candidate tumor suppressor gene Hicl exhibit developmental defects of structures affected in the Miller-Dieker syndrome
3. Functional evidence for a breast cancer suppresor gene on shromosome 17
4. Evidence implicating at least two genes on chromosome 17 p in breast carcinogenesis
5. Evidence for a gene on 17 p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations
6. Purification of CpG islands using a methylated DNA binding column
7. The carboxy-terminal end of the candidate tumor suppressor gene HIC-1 is phylogenetically conserved
8. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer
9. Evolutionary divergence in the broad complex tramtrak and bric a brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer
10. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
11. Concordant methylation of the ER and N33 genes in glioblastoma multiforme
12. Prognostic significance of loss of heterozygosity at loci on chromosome 17 p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene
13. Regional DNA hypermethylation at D17S5 precedes 17 p structural changes in the progression of renal tumors
14. P53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17 p13.3
15. Cancer-specific region of hypermethylation identified within the HIC-1 putative tumour suppressor gene in acute myeloid leukaemia
16. Five distinct deleted regions on chromosome 17 defining different subsets of human primary breast tumours
17. An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170
18. Consortium study on 1280 breast carcinomas: Allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters
19. Allelic deletion on chromosome 17p13.3 in early ovarian cancer
20. Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within the distal region of chromosome band 17p13.3
21. The p53 tumour suppressor gene
22. Suppression of tumorigenicity of breast cancer cells by transfer of human chromosome 17 does not require transferred BRCA1 and p53 genes
23. P53 gene mRNA expression and chromosome 17p allele loss in breast cancer
24. P53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters
25. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium term follow up
26. P53 and breast cancer